In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula (AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

An object of the present invention is to provide: a developer that can provide a thermosensitive recording material excellent in color development sensitivity and storage stability; and a thermosensitive recording material obtained using the developer. The object is achieved by a developer including a compound represented by the following Formula (1).

##STR00001##

In Formula (1), a, A, and L are as follows: a is an integer selected from 1 to 5, A is each independently a fluoro group or a perfluoroalkyl group, and L is any of functional groups represented by the following Formula (2):

##STR00002##

wherein in Formula (2), R is a C.sub.1-C.sub.4 alkyl group, and * represents a binding site to a sulfur atom in Formula (1).

An object of the present invention is to provide: a developer that can provide a thermosensitive recording material excellent in color development sensitivity and storage stability; and a thermosensitive recording material obtained using the developer. The object is achieved by a developer including a compound represented by the following Formula (1).

##STR00001##

In Formula (1), a, A, and L are as follows: a is an integer selected from 1 to 5, A is each independently a fluoro group or a perfluoroalkyl group, and L is any of functional groups represented by the following Formula (2):

##STR00002##

wherein in Formula (2), R is a C.sub.1-C.sub.4 alkyl group, and * represents a binding site to a sulfur atom in Formula (1).

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

The invention relates to a color developer of the formula (I), wherein m and n independently of one another are ≥1, Ar.sup.1 is an unsubstinited or substituted (hetero) aromatic radical, Ar.sup.2 is an unsubstituted or substituted phenyl radical, and Y is at least one (m+n)-times substituted benzene or naphthalene group, and to a heat-sensitive recording material, comprising a supporting substrate and a heat-sensitive color-forming layer containing at least one color former and at least one phenol-free color developer, wherein the at least one color developer is the compound of the formula (I). The invention further relates to a method for producing said heat-sensitive recording material.

##STR00001##

The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3inhibition.

##STR00001##